The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.25
Bid: 19.00
Ask: 19.50
Change: -0.25 (-1.28%)
Spread: 0.50 (2.632%)
Open: 19.50
High: 19.50
Low: 18.50
Prev. Close: 19.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Geomerics IP Validation

27 Jul 2006 07:00

Angle PLC27 July 2006 For Immediate Release 27 July 2006 ANGLE plc ("ANGLE") Core intellectual property validation: Geomerics Ltd ("Geomerics") ANGLE, the venture management and consulting company specialising in thecommercialisation of technology, is pleased to announce the validation ofProgeny(R) company Geomerics' core intellectual property through demonstrationof a revolutionary new computer graphics technology. Geomerics has unveiled technology that allows real-time radiosity in computergames utilising commodity graphics processing hardware. Radiosity, the processof fully modelling the subtle effects arising from the inter-reflections oflight between surfaces, dominates many real-world situations. Until now, sucheffects were considered beyond the reach of real-time techniques producingnoticeably 'unrealistic' lighting in computer games. Geomerics' breakthrough dynamic radiosity solution enables the full range oflighting effects, including inter-reflections, to be updated in real-time,providing significantly greater realism and impact. Geomerics has applied itscore intellectual property, based around geometric algebra, to produce thisradical new radiosity solution. The solution allows for fully dynamic lighting,including point spot-lights, area lights, texture-based lighting, glowingobjects and the projection of video onto geometry, all on common video hardware. Geomerics provided the first live demonstration of the technology at the DevelopConference in Brighton on 13 July. ANGLE is pleased to announce that subsequentindustry response to the technology was considerable, with over fifty commercialenquiries including many leading games developers. ANGLE believes that thisdemonstration is a validation of the power of Geomerics' core intellectualproperty and looks forward to both further applications and imminent commercialvalidation. Further details, including screenshots, movies, and previews of other Geomericssolutions can be found at www.geomerics.com Chris Doran, CEO and founder of Geomerics commented, "This revolutionarylighting technique is a demonstration of the potential of Geomerics' technologyand our unique approach to games middleware and technology licensing. Geometricalgebra provides opportunities for totally new solutions in a huge range ofgames problems, from lighting to physics and beyond." Andrew Newland, CEO of ANGLE, commented, "We are excited to view the validationof Geomerics' core intellectual property. The company has made good progress todate and we look forward to further applications of the core intellectualproperty in the near future." Geomerics, founded by ANGLE in 2005, is commercialising geometric algebratechnology developed at the University of Cambridge, UK, and in the USA. Thistechnology has applicability in the computer games industry, where it enablesfilm-quality visuals to be generated in real-time; in electromagnetic modelling,where a step-change in accuracy and speed can be seen; and in a wide selectionof other industries, to be announced by the company in due course. Geomerics is an ANGLE Progeny(R) Company. For further information ANGLE plc +44 1483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director of New Ventures GeomericsAlison Beasley of Lincoln Beasley PR +44 1608 645756 Buchanan CommunicationsRichard Darby, Amy Rajendran +44 207 466 5000 Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from officesin the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery
5th Dec 20237:00 amRNSANGLE launches Portrait+ CTC kit at SABCS
9th Nov 20237:00 amRNSLaunch of PD-L1 test to support cancer studies
9th Nov 20237:00 amRNSTrading and business update
25th Oct 20237:00 amRNSSupporting characterisation of CTCs in HNSCC
3rd Oct 20237:00 amRNSParsortix outperforms standard for DTC harvest
29th Sep 20237:00 amRNSParsortix system showcased at ACTC conference
7th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
4th Sep 20237:00 amRNSANGLE launch of Portrait Flex assay
15th Aug 20237:00 amRNSANGLE notice of interim results
28th Jun 20234:54 pmRNSResult of 2023 Annual General Meeting
27th Jun 202312:24 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSANGLE announces senior management appointments
25th May 20237:00 amRNSPharma services contract with Artios Pharma
22nd May 20237:00 amRNSBoard change - appointment of new Chairman
21st Apr 202312:04 pmRNSANGLE presentation via Investor Meet Company
21st Apr 20237:00 amRNSResults for the year ended 31 December 2022
19th Apr 20237:00 amRNSANGLE announces partnership with BioView
17th Apr 20237:00 amRNSANGLE Parsortix poster presented at AACR 2023
13th Apr 20237:00 amRNSPharma Services Contract with Crescendo Biologics
3rd Apr 20237:00 amRNSNotice of Preliminary Results and Webcast
10th Mar 20237:00 amRNSIssue of LTIP Options and Share Options
9th Mar 20233:03 pmRNSHolding(s) in Company
9th Feb 20232:44 pmRNSDirector/PDMR shareholding
19th Jan 20237:00 amRNSAppointment of Non-Executive Director
11th Jan 20235:20 pmRNSHolding(s) in Company
10th Jan 20236:20 pmRNSHolding(s) in Company
6th Jan 202311:05 amRNSSecond Price Monitoring Extn
6th Jan 202311:00 amRNSPrice Monitoring Extension
5th Jan 20239:05 amRNSSecond Price Monitoring Extn
5th Jan 20239:00 amRNSPrice Monitoring Extension
5th Jan 20237:01 amRNSAppointment of Non-Executive Director
5th Jan 20237:00 amRNSBusiness Update
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.